The Board of Directors of CDG Petchem Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2025 - Q4FY25, Q4FY2025, FY2024-25, FY2025.

Gene sequencing enabled researchers to identify the specific milk protein that triggered a patient’s eosinophilic esophagitis ...

The Board of Directors of Hexaware Technologies Limited, at its meeting held today have approved the financial results of the ...

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Eosinophilic Esophagitis ORLANDO, FLORIDA / ACCESS Newswire / April 28, 2025 / The Assistance Fund, an independe ...

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Eosinophilic Esophagitis ORLANDO, FLORIDA / ACCESS Newswire / April 28, 2025 / The Assistance Fund, an ...

New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom ...

Trouble swallowing can cause anxiety, and anxiety can cause trouble swallowing. Certain techniques can help you break the ...

Sebela Pharma announces positive results from phase 3 TRIUMpH programme of tegoprazan in GERD: Braintree, Massachusetts Friday, April 25, 2025, 18:00 Hrs [IST] Braintree Laborator ...

“Tegoprazan offers an exciting new treatment option for individuals suffering from GERD, helping to address the substantial unmet need of patients not well-controlled by conventional PPI therapy,” ...

Eupraxia's CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. On April 24, 2025, Eupraxia Pharmaceuticals announced its participation in several ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...